When Licensing Becomes the Bottleneck: Lessons from a Sponsor on COAs, eCOA Vendors, and Getting It Right

FDA clinical outcome assessment COA licensing has a reputation in the industry, and it's not a flattering one.

"It is often called the bottleneck of COA," says Mark Wade, Global Practice Leader and COA SME, in a recent LifeSci Talks episode with Stacey Higgins, who holds nearly two decades of experience navigating licensing, vendor relationships, and global study complexity. What was discussed was not frustration, but rather a clear pattern of where sponsors tend to underestimate risk.

The Core Problem: No Two Licensors Are the Same

Most teams assume licensing is linear:

Identify instrument > Contact owner > Execute agreement > Move forward

In reality, no two licensors operate the same way. While the average licensing timeline has settled at around 30 days, timelines can vary drastically. Some agreements can close in a single day, while others take far longer.

"Every owner has a different way of managing their licensing. There isn't a black and white that you can put a timestamp on and say, licensing is always going to take this long." — Stacey Higgins | LifeSci Talks: Licensing Challenges vs. eCOA Vendor Capabilities.

The variability runs deep. One licensor might charge per patient administration, whereas another might charge per language, per site, or by some combination of factors you've never encountered before. And even if you've worked with a particular owner on a previous trial and think you know how they operate, don't assume the next engagement will look the same. Stacey notes that around five to ten percent of licensors make adjustments from year to year—sometimes updating their fees, sometimes changing how they want the license executed, and occasionally reworking the contract itself.

That last scenario is the most disruptive. When a contract changes, it often means looping in legal teams on both sides. The sponsor’s legal department is trying to protect the company’s interests, while the owner is protecting their life's work, and getting both sides to agree takes time that clinical teams rarely have to spare.

When leading COA licensing strategy, the answer needs to be proactive planning. Instead of waiting until a study formally launches, licensing discussions should begin at the portfolio planning stage, identifying likely instruments early—including observer-reported outcome tools and clinician-reported outcome measures—and initiating agreements in advance. With centralized budget oversight, teams can absorb upfront licensing work to reduce downstream risk.

The eCOA Vendor Relationship: Involvement Is Not Optional

Licensing is only the first pressure point.

The second is vendor alignment.

Electronic implementation introduces another layer of dependency between the eCOA vendor and instrument owner. If that relationship is not aligned or fractures, whether it’s in implementation details, contractual boundaries, or execution standards, the fallout rarely surfaces early. More often than not, it occurs mid-study, when timelines are already committed to and switching vendors becomes disruptive at best.

While sponsors don’t need to manage vendor contracts directly, visibility is key to ensure alignment across all parties. When misalignments or discrepancies exist between what an owner permits and what a vendor executes, it risks data integrity.

Why "Just Use Google Translate" Misses the Point of Linguistic Validation

Machine translation tools are improving rapidly, and efficiency expectations are rising with it. However, while pressure to speed up translation cycles is growing, the goal of a validated translation is critical to keep top of mind. It’s not just accuracy in a dictionary sense, but also ensuring that the meaning a patient takes from a question in translation is the same meaning the instrument developer intended in the original language.

Consider a simple phrase: "Why do I feel blue today?"

Translate this through a machine and it's likely to come back as the color blue. The emotion, sadness, or low mood is what the instrument is trying to capture, and that is exactly what automated translation loses.

The process of conceptual validation—ensuring that a concept survives translation—requires multiple steps, iterative review, and critically, cognitive debriefing with patients who are actually living with the relevant disease. Without these, you risk scientific integrity and regulatory scrutiny.

Navigating a Crowded Vendor Landscape

The clinical trial ecosystem has changed dramatically over the past two decades.

Estimates now place the number of active eCOA vendors somewhere between 20 and 50, a dramatic increase from two decades ago. Language service providers have proliferated similarly. For sponsors, this creates a different kind of problem—not a shortage of options, but an overwhelming abundance of them, with widely varying levels of experience and capability.

Vendor selection requires a rigorous evaluation of their infrastructure, their linguistic validation process, their tenure in the industry, and the source of their core business. A translation company that has built its reputation on general commercial translation is a very different proposition from one whose expertise is rooted in clinical COA work.

The Patient at the Center

Across licensing, vendor management, and translation, there’s one constant stakeholder who doesn’t sit in operational meetings: the patient.

When something goes wrong—whether a licensing delay, a translation shortcut, or a vendor misalignment—the person who ultimately pays the price is the patient waiting for the trial to reach them.

Sponsor involvement, despite being time-consuming and occasionally uncomfortable, is worth the investment. It's not about micromanaging vendors. It's about making sure that at every point in the chain—from licensing through translation to electronic implementation—someone with responsibility for the outcome is paying attention.

Key Takeaways

For sponsors managing FDA clinical outcome assessments (COAs) in global trials, these lessons translate into clear operational priorities:

• Start licensing before you think you need to.
• Track changes to licensing terms proactively.
• Stay involved with your eCOA vendor to ensure alignment.
• Insist on proper linguistic validation that follows industry best practices.
• Vet vendors rigorously and don't confuse general translation capability with COA expertise.

The challenges discussed across unpredictable licensing timelines, fragmented vendor relationships, the irreplaceable rigor of linguistic validation, and the ever-expanding landscape of providers to evaluate and manage, are not isolated issues but rather structural friction points across the FDA clinical outcome assessment lifecycle.

For organizations looking to reduce that friction, oversight across licensing, validated translation, and eCOA implementation can materially reduce risk exposure. At TransPerfect Life Sciences, these services operate under one coordinated framework to reduce handoffs, improve alignment, and protect endpoint integrity from study startup through post-market surveillance. By doing so, sponsors can keep their focus where it matters most: ensuring that patients receive the trial treatment they’re waiting for, on time and without compromise. In the end, COA strategy isn’t about paperwork, but about protecting patients and the data that represents them.

Want the Full Discussion?

This article captures the themes discussed in the episode of LifeSci Talks: Licensing Challenges vs. eCOA Vendor Capabilities.

The full conversation goes deeper into real-world sponsor experiences navigating licensing variability, vendor conflict, and linguistic validation pressure.